Comparison · NCT02924727-b624eed9
LCZ696 (Sacubitril/Valsartan) vs Ramipril: All-cause Mortality for Full Analysis Set (FAS)
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. LCZ696 (Sacubitril/Valsartan) vs Ramipril: All-cause Mortality for Full Analysis Set (FAS). Trial comparisons, record NCT02924727-b624eed9. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02924727-b624eed9
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0753 | 0.0661 | 0.0856 | wilson | |
| Risk in group 2 | 0.0855 | 0.0757 | 0.0964 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0102 | -0.0244 | 0.00397 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.88 | 0.738 | 1.05 | log | |
| Odds ratio, group 1 over group 2 | 0.871 | 0.719 | 1.06 | log | |
| Number needed to treat, for one fewer participant with the outcome on LCZ696 (Sacubitril/Valsartan) than on Ramipril | 97.9 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | LCZ696 (Sacubitril/Valsartan) | Following randomization, patients received LCZ696 in titrated doses from level 1 up to level 3 (50, 100 and 200 mg twice daily).~Patients were required to take a total of two pills, (one tablet from the LCZ696 pack and one capsule from Ramipril matching placebo pack) twice a day for the duration of the study.~Patients randomized to LCZ who were previously treated with ACE inhibitors, receiving the last dose of that agent during the last 36 hours prior to randomization, received a valsartan bridge for one day. These patients received two doses of valsartan for 1 day in a blinded manner prior to beginning double-blind LCZ696 treatment. | 213 | 2,830 | OG000 |
| Group 2 | Ramipril | Following randomization, patients received Ramipril in titrated doses from level 1 up to level 3 (1.25, 2.5 and 5 mg twice daily).~Patients were required to take a total of two pills, (one capsule from the Ramipril pack and one tablet from LCZ696 matching placebo pack) twice a day for the duration of the study.~Patients randomized to Ramipril who were previously treated with ACE inhibitors, receiving the last dose of that agent during the last 36 hours prior to randomization immediately started on double-blind ramipril; however, to maintain double blind/double dummy of the valsartan bridge, these patients received two doses of matching valsartan placebo for 1 day in a blinded manner prior to beginning double-blind LCZ696 placebo. | 242 | 2,831 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- All-cause Mortality for Full Analysis Set (FAS)
- Description
- All-cause mortality defined as deaths related to Cardiovascular (CV) and non-CV events for patients in the Full Analysis Set up to a cut-off date of 31-Dec-2020.
- Time frame
- Time from randomization to death (approximately up to 43 months)
- Population
- Full Analysis Set
Source ClinicalTrials.gov
Trial
- Title
- Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MI
- NCT number
- NCT02924727
- Phases
- PHASE3
- Conditions
- Acute Myocardial Infarction
- Interventions
- LCZ696 (sacubitril/valsartan), Ramipril, Placebo of LCZ696, Placebo of ramipril, Valsartan, Placebo of valsartan
- Lead sponsor
- Novartis Pharmaceuticals
- Results first posted
- 2023-06-22
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02924727?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02924727-b624eed9